# Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

> **NCT03377400** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03377400
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-14
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03377400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03377400, "Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03377400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*